Drug intelligence / Profile preview

SCB-2023

Development stage: Unknown
Lead developer: Clover Biopharmaceuticals
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SCB-2023 is a trivalent recombinant SARS-CoV-2 spike (S) protein subunit vaccine candidate developed as a booster for COVID-19. It is designed using Clover Biopharmaceuticals' Trimer-Tag technology platform and targets multiple variants of SARS-CoV-2 by presenting stabilized trimeric S-proteins from different strains. The vaccine is administered via intramuscular injection and aims to elicit broad neutralizing antibody responses against circulating COVID-19 variants. Clinical studies are comparing its immunogenicity and safety profile to the earlier monovalent prototype, SCB-2019[1][5][8].

Targets

RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on SCB-2023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCB-2023.

Explore the full profile